TCDA - Tricida, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
-0.07 (-0.24%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close29.10
Bid26.18 x 800
Ask30.25 x 900
Day's Range28.66 - 30.34
52 Week Range24.75 - 31.20
Avg. Volume2,337,400
Market Cap1.222B
PE Ratio (TTM)N/A
EPS (TTM)-27.12
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wire15 days ago

    Tricida Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Tricida, Inc. , a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-dosed polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease, today announced the closing of its initial public offering of 13,455,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase ...

  • The Wall Street Journal15 days ago

    [$$] Biotech Companies Continue IPO Hot Streak, But For How Long?

    Inc., after five biotech IPOs were completed the week before. With public investors eager to tap into biotech innovation, startups this year have streamed onto Nasdaq despite market volatility that would have slowed offerings previously. Biotech IPO investors are taking a portfolio approach not unlike that of venture capitalists, said Cooley attorney Div Gupta.

  • We're sorry this is all we were able to find about this topic.